NFE2L2 and amyotrophic lateral sclerosis: These findings position DMF as a clinically relevant compound capable of targeting multiple ALS-related pathomechanisms via Nrf2 activation, with translational value supported by existing human safety data and ongoing formulation development for central nervous system (CNS) indications.